R D Harvey
Overview
Explore the profile of R D Harvey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papadopoulos K, El-Rayes B, Tolcher A, Patnaik A, Rasco D, Harvey R, et al.
Br J Cancer
. 2017 Oct;
117(11):1592-1599.
PMID: 28972963
Background: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2...
2.
Wu B, Lewis L, Harvey R, Rasmussen E, Gamelin E, Sun Y, et al.
Clin Pharmacol Ther
. 2017 Jan;
102(2):313-320.
PMID: 28074547
Clearance of trebananib (AMG 386), a 64-kD antiangiogenic peptibody, has been associated with estimated glomerular filtration rate (eGFR). We prospectively evaluated trebananib pharmacokinetics and safety/tolerability in advanced solid tumor patients...
3.
Baz R, Lin H, Hui A, Harvey R, Colson K, Gallop K, et al.
Support Care Cancer
. 2015 Feb;
23(9):2789-97.
PMID: 25708126
Purpose: Little qualitative research exploring the impact of multiple myeloma (MM) and its treatment on the health-related quality of life (HRQL) of patients has been published. This study aimed to...
4.
Singh K, Stempora L, Harvey R, Kirk A, Larsen C, Blazar B, et al.
Am J Transplant
. 2014 Nov;
14(12):2691-703.
PMID: 25359003
Many critical issues remain concerning how best to deploy adoptive regulatory T cell (Treg) immunotherapy to the clinic. These include a determination of their pharmacokinetic characteristics, their optimal dose, their...
5.
Tran D, Harvey R, Meeks S, Chapman R, Kempton C
Haemophilia
. 2014 Apr;
20(4):e344-6.
PMID: 24750497
No abstract available.
6.
Harvey R
Clin Pharmacol Ther
. 2014 Apr;
96(2):214-23.
PMID: 24690569
Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity...
7.
Harvey R, Owonikoko T, Lewis C, Akintayo A, Chen Z, Tighiouart M, et al.
Br J Cancer
. 2013 Jan;
108(4):762-5.
PMID: 23322195
Background: This phase 1 trial utilising a Bayesian continual reassessment method evaluated bortezomib and sunitinib to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended doses of the...
8.
Goatman K, Philip S, Fleming A, Harvey R, Swa K, Styles C, et al.
Diabet Med
. 2011 Oct;
29(6):776-83.
PMID: 22023553
Aims: To develop and evaluate an image grading external quality assurance system for the Scottish Diabetic Retinopathy Screening Programme. Method: A web-based image grading system was developed which closely matches...
9.
Harvey R, Barlow D, Brain A, Heenan R, Zuberi S, Zuberi T, et al.
Chem Phys Lipids
. 2011 Apr;
164(5):341-50.
PMID: 21477585
Five non-ionic dialkylglycerol poly(oxyethylene) ether surfactants, designated 2C(m)E(n) (where m, the number of carbons in each alkyl chain=16 or 18, and n, the number of oxyethylene units=12, 16 or 17)...
10.
Harvey R, Nettles J, Wang B, Sun S, Lonial S
Leukemia
. 2009 Nov;
23(11):1939-40.
PMID: 19904281
No abstract available.